Satoru Iwashima

Dr. Satoru Iwashima

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2007 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
SISatoru Iwashima
Satoru Iwashima
TIT. Ishikawa
T. Ishikawa
TOT. Ohzeki
T. Ohzeki

31 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Masaaki MoriMasaaki Mori
Masaaki Mori
THTakuma Hara
Takuma Hara
MKMasako Kikuchi
Masako Kikuchi
HSHiroyuki Shimizu
Hiroyuki Shimizu
TMTomoyuki Miyamoto
Tomoyuki Miyamoto
SFShigeto Fuse
Shigeto Fuse
We compared the efficacy and safety of infliximab with intravenous immunoglobulin (IVIG), a standard therapy, in a phase 3 trial (NCT01596335) for Japanese patients with Kawasaki disease (KD) showing persistent fever after initial IVIG. Patients with initial IVIG-refractory KD, aged 1–10 years, received a single dose of IV infliximab 5 mg/kg or IV polyethylene glycol-treated human immunoglobulin (VGIH) 2 g/kg on day 0. Primary outcome was defervescence rate within 48 h after the start of treatment. Safety was evaluated through day 56. Overall, 31 patients were randomized (infliximab, n = 16; VGIH, n = 15); 31.3% and 60.0% patients discontinued due to worsening KD. Defervescence rate within 48 h was greater with infliximab (76.7%) than VGIH (37.0%) (p = 0.023), and defervescence was achieved earlier with infliximab (p = 0.0072). Coronary artery lesions occurred in 1 (6.3%) and 3 (20.0%) patients receiving infliximab and VGIH, respectively, up to day 21. Adverse events occurred in 15 (93.8%) and 15 (100.0%) patients in the infliximab and VGIH groups, respectively. No serious adverse events in the infliximab group and one in the VGIH group were observed. Infliximab improved the defervescence rate within 48 h and time to defervescence versus standard therapy, and was well tolerated in patients with IVIG-refractory KD.

1 March 2011 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
SISatoru Iwashima
Satoru Iwashima
MKMituaki Kimura
Mituaki Kimura
TITakamichi Ishikawa
Takamichi Ishikawa
TOTakehiko Ohzeki
Takehiko Ohzeki

18 January 2013 in World Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
SISatoru Iwashima
Satoru Iwashima
TITakamichi Ishikawa
Takamichi Ishikawa

1 September 2013 in Early Human Development
Verified
Journal Article
Closed access
SISatoru Iwashima
Satoru Iwashima
KSKatuyuki Sekii
Katuyuki Sekii
TITakamichi Ishikawa
Takamichi Ishikawa
HIHiroaki Itou
Hiroaki Itou

26 September 2018 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
YIYutaka Ito
Yutaka Ito
SISatoru Iwashima
Satoru Iwashima
SHSatoshi Hayano
Satoshi Hayano
TNTomohiro Nishio
Tomohiro Nishio
RSRyosuke Shiozawa
Ryosuke Shiozawa
KUKeiichi Uemura
Keiichi Uemura